Spider venom-inspired peptide to revolutionize sexual dysfunction medicine for both men and women

> Sexual dysfunction affects hundreds of millions of people worldwide, yet remains one of the most overlooked areas in modern medicine. Another Day Pharma, a UK-based pharma company, wants to change that. The company is developing **BZ371A**, a novel topical therapy with a unique mechanism of action rooted in nature – specifically, a peptide derived from **the venom of the Phoneutria nigriventer spider.** This compound could present new opportunities in treating erectile dysfunction (ED) and female sexual dysfunction (FSD) by bypassing conventional neurological pathways and directly stimulating nitric oxide production.

> Approximately one-third of patients cannot use PDE5 inhibitors, such as tadalafil because of potential interactions with cardiovascular medications or adverse effects. Systemic vasodilation can cause headache, tachycardia, and hypotension – leading to dizziness and posing risks in patients with cardiovascular disease. The formulation of BZ371A allows it to penetrate the penile tissue **without significant systemic distribution.** Moreover, due to its mechanism of action, BZ371A acts as a trigger, stimulating the cells to produce their own nitric oxide. This means that BZ371A can be **rapidly degraded after exerting its effect, minimizing the potential for systemic side effects, while its therapeutic benefit lasts up to 24 hours.**

> BZ371A is a unique peptide with an innovative and exclusive mechanism of action. It is currently the only molecule capable of inducing local NO production through the activation of specific enzymes in the smooth muscle tissue. Its formulation was developed to stabilize the peptide and enable its permeation through the penile skin, reaching the corpus cavernosum in therapeutically relevant concentrations. To date, **no other approved drug has demonstrated this specific mechanism of action.**

> BZ731A offers a fundamentally different approach for treating hypoactive sexual desire disorder in female sexual dysfunction. It is a non-hormonal, topical treatment designed to trigger a local arousal response independent of neurological or psychological desire. In effect, the physiological stimulation acts as the precursor to desire, rather than relying on it – reversing the traditional causal pathway. This mechanism has the potential to restore **a more natural sexual response pattern in affected women.**

[Ongoing and completed clinical trials (phase 1 and 2)](https://clinicaltrials.gov/search?term=BZ371A)

Talk about getting bit by the love bug! 😂 Just hope it doesn’t come with spider senses tho, cuz I’m not ready to feel everything THAT acutely!